UNLABELLED: To objectively evaluate the performance of new vaginal dosage forms, it is important to determine their time of residence and their distribution. This paper describes the in vivo characteristics of a reference and test product in this situation. METHOD: A randomised cross-over study was performed in the same phase of the menstrual cycle in eight pre-menopausal women. The retention and distribution of a commercially available vaginal clotrimazole cream and a test gel product, each "labelled" with 99mTc-DTPA was assessed by gamma scintigraphy for 24 h after administration of the products. Mass balance analysis was attempted by collecting and counting sanitary napkins worn for the study time. RESULTS: Within individuals there was little variation in the clearance of the formulations, but wide variation between individuals with a range between 81 and 1% of the administered doses retained by 24 h. The losses appeared to occur mainly at times of urination with 12 +/- 8% (cream) and 20 +/- 23% (gel) collected on the sanitary napkins, but 46 +/- 34% (cream) and 38 +/- 22% gel activity not accounted for by 24 h. The intravaginal distribution of activity was similar for each product. CONCLUSIONS: Radioactive tracer methods are useful in assessing and comparing vaginal dosage forms.
RCT Entities:
UNLABELLED: To objectively evaluate the performance of new vaginal dosage forms, it is important to determine their time of residence and their distribution. This paper describes the in vivo characteristics of a reference and test product in this situation. METHOD: A randomised cross-over study was performed in the same phase of the menstrual cycle in eight pre-menopausal women. The retention and distribution of a commercially available vaginal clotrimazole cream and a test gel product, each "labelled" with 99mTc-DTPA was assessed by gamma scintigraphy for 24 h after administration of the products. Mass balance analysis was attempted by collecting and counting sanitary napkins worn for the study time. RESULTS: Within individuals there was little variation in the clearance of the formulations, but wide variation between individuals with a range between 81 and 1% of the administered doses retained by 24 h. The losses appeared to occur mainly at times of urination with 12 +/- 8% (cream) and 20 +/- 23% (gel) collected on the sanitary napkins, but 46 +/- 34% (cream) and 38 +/- 22% gel activity not accounted for by 24 h. The intravaginal distribution of activity was similar for each product. CONCLUSIONS: Radioactive tracer methods are useful in assessing and comparing vaginal dosage forms.
Authors: Nicolette A Louissaint; Edward J Fuchs; Rahul P Bakshi; Sridhar Nimmagadda; Yong Du; Katarzyna J Macura; Karen E King; Richard Wahl; Arthur J Goldsmith; Brian Caffo; Ying Jun Cao; Jean Anderson; Craig W Hendrix Journal: J Infect Dis Date: 2012-01-25 Impact factor: 5.226
Authors: Claire J Forbes; Deborah Lowry; Leslie Geer; Ronald S Veazey; Robin J Shattock; Per Johan Klasse; Mark Mitchnick; Laurie Goldman; Lara A Doyle; Brendan C O Muldoon; A David Woolfson; John P Moore; R Karl Malcolm Journal: J Control Release Date: 2011-08-12 Impact factor: 9.776
Authors: Laura M Ensign; Benjamin C Tang; Ying-Ying Wang; Terence A Tse; Timothy Hoen; Richard Cone; Justin Hanes Journal: Sci Transl Med Date: 2012-06-13 Impact factor: 17.956
Authors: Claire J Forbes; Clare F McCoy; Diarmaid J Murphy; A David Woolfson; John P Moore; Abbey Evans; Robin J Shattock; R Karl Malcolm Journal: J Pharm Sci Date: 2014-03-01 Impact factor: 3.534